vaccine adjuvant comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
| Property | Value | Notes |
|---|---|---|
| Storage temperature, powder | -20 °C or lower | Protect from light and moisture |
| Storage temperature, reconstituted | 2-8 °C | Use within days |
| Purity testing | Reversed-phase HPLC | Separates truncation products |
| Mass confirmation | Mass spectrometry | Detects deamidation and oxidation |
| Common salt forms | Acetate or trifluoroacetate | Affects solubility and weighing |
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
McKew said that "Putin and his minions have spent the past 15 years ranting about how the West (specifically NATO) wants a new Cold War". She suggested that "fighting a new Cold War would be in America's interest", adding "We won the last Cold War. We will win the next one too". The New Republic editor Jeet Heer criticised McKew's suggestion as "troubling" and for "wildly overstating the extent of Russian ambitions and power". Heer said that unlike the old Cold War, "Current U.S. troubles with Russia aren't the result of ideological differences ... and are intensely localized along Russia's borders, in countries like the Ukraine and Georgia". Jeremy Shapiro, a senior fellow in the Brookings Institution, wrote in his blog post at RealClearPolitics, referring to the US–Russia relations: "A drift into a new Cold War has seemed the inevitable result" of "Russian–Western confrontation" over Eastern European counties such as Ukraine, Moldova and Georgia. In August 2017, Russian Deputy Foreign Minister Sergei Ryabkov denied claims that the US and Russia were having another cold war, despite ongoing tensions between the two countries over Ukraine and Syria, and newer US sanctions against Russia. The University of East Anglia graduate student Oliver Steward, as well as the Casimir Pulaski Foundation senior fellow Stanisław Koziej, attributed the Russia's Zapad 2017 exercise in Belarus as part of the new Cold War between Russia and the West.
== Further reading == Appanna, Varun P.; Auger, Christopher; Thomas, Sean C.; Omri, Abdelwahab (13 June 2014). "Fumarate metabolism and ATP production in Pseudomonas fluorescens exposed to nitrosative stress". Antonie van Leeuwenhoek. 106 (3): 431–438. doi:10.1007/s10482-014-0211-7. PMID 24923559. S2CID 1124142. Cabrefiga, J.; Frances, J.; Montesinos, E.; Bonaterra, A. (1 October 2014). "Improvement of a dry formulation of Pseudomonas fluorescens EPS62e for fire blight disease biocontrol by combination of culture osmoadaptation with a freeze-drying lyoprotectant". Journal of Applied Microbiology. 117 (4): 1122–1131. doi:10.1111/jam.12582. PMID 24947806.
== References == M. Sakthi Balan; Kamala Krithivasan; Y. Sivasubramanyam (2001). Peptide Computing - Universality and Complexity. Lecture Notes in Computer Science. Vol. 2340. pp. 290–299. doi:10.1007/3-540-48017-X_27. ISBN 978-3-540-43775-8. Hubert Hug & Rainer Schuler (2001). "Strategies for the development of a peptide computer". Bioinformatics. 17 (4): 364–368. doi:10.1093/bioinformatics/17.4.364. PMID 11301306.
=== Leon Carp === Leon Carp is played by Martin Mull. Leon, originally as Roseanne's boss at Rodbell's Luncheonette and later as her business partner in The Lanford Lunchbox, he is portrayed as a foe to Roseanne; although they have a contentious relationship at times, Leon gradually becomes a close friend of the Conners, ultimately becoming a surrogate family member. As a gay man, he is occasionally seen dating many men and having romantic troubles; however, he later marries his life partner Scott (Fred Willard) in a very public ceremony. In the ninth season, they visit the Conner residence bearing gifts for Darlene and David's new baby, Harris, proclaiming themselves as the infant's Aunt Scott and Aunt Leon. Near the end of the episode, they announce their plans to adopt a little girl. Leon's role in the series expands significantly in the eighth and ninth seasons, as he is featured in more episodes. He is especially upset when Roseanne wins the lottery, but Roseanne and Jackie end up relinquishing control of the restaurant to Leon and Nancy. Leon is a Republican, and holds George Bush in high regard. He also is shown throughout the series' run to be a fan of Liza Minnelli, as well as Broadway musicals. Leon did not appear in season 10, nor did he appear on the spin-off series.
== Applications == The first demonstration of the use of peptoids was in screening a combinatorial library of diverse peptoids, which yielded novel high-affinity ligands for 7-transmembrane G-protein-couple receptors. Peptoids have been developed as candidates for a range of different biomedical applications, including antimicrobial agents, synthetic lung surfactants, ligands for various proteins including Src Homology 3 (SH3 domain), Vascular Endothelial Growth Factor (VEGF) receptor 2, and antibody Immunoglobulin G biomarkers for the identification of Alzheimer's disease. Due to their advantageous characteristics as described above, peptoids are also being actively developed for use in nanotechnology, an area in which they may play an important role.
Sources: en.wikipedia.org
The first whole genome sequencing study to comprehensively catalog de novo structural variation at a much higher resolution than DNA microarray studies has shown that the mutation rate is approximately 20% and not elevated in autism compared to sibling controls. Structural variants in individuals with autism are much larger and four times more likely to disrupt genes, mirroring findings from CNV studies. CNV studies were closely followed by exome sequencing studies, which sequence the 1–2% of the genome that codes for proteins (the "exome"). These studies found that de novo gene inactivating mutations were observed in approximately 20% of individuals with autism, compared to 10% of unaffected siblings, suggesting the etiology of autism is driven by these mutations in around 10% of cases. There are predicted to be 350-450 genes that significantly increase susceptibility to autism when impacted by inactivating de novo mutations. A further 12% of cases are predicted to be caused by protein altering missense mutations that change an amino acid but do not inactivate a gene. Therefore, approximately 30% of individuals with autism have a spontaneous de novo large CNV that deletes or duplicates genes, or mutation that changes the amino acid code of an individual gene. A further 5–10% of cases have inherited structural variation at loci known to be associated with autism, and these known structural variants may arise de novo in the parents of affected children.
When Winston Churchill became Prime Minister in 1940, he bypassed the War Office altogether, and appointed himself Minister of Defence (though there was, curiously, no ministry of defence until 1947). Clement Attlee continued this arrangement when he came to power in 1945, but appointed a separate Minister of Defence for the first time in 1947. In 1964, the present form of the Ministry of Defence was established, unifying the War Office, Admiralty, and Air Ministry.
Approximately 24,700,000 tons of ethylbenzene were produced in 1999. Highly instructive but of far less industrial significance is the Friedel-Crafts alkylation of benzene (and many other aromatic rings) using an alkyl halide in the presence of a strong Lewis acid catalyst. Similarly, the Friedel-Crafts acylation is a related example of electrophilic aromatic substitution. The reaction involves the acylation of benzene (or many other aromatic rings) with an acyl chloride using a strong Lewis acid catalyst such as aluminium chloride or Iron(III) chloride.
The blood-brain barrier (BBB) is a semipermeable membrane that separates the blood from the brain's interstitial fluid. It is formed by tight junctions between endothelial cells, astrocytes, and pericytes in the brain's capillaries, and has high electrical resistance. The BBB is crucial for protecting the brain from pathogens and toxic substances, maintaining homeostasis, and preventing alterations to neuronal functions. However, some diseases can damage the BBB, causing leakage. Research suggests that increasing intake of vitamins and antioxidants, as well as reducing stress, can help restore the BBB. Due to its selective nature, the BBB restricts the passive diffusion of solutes, large and hydrophilic molecules, and immune factors, making it challenging to deliver pharmaceuticals directly to the brain.
Through the development of a peptide microarray platform, his group uncovered mechanisms of DNA methylation maintenance and defined modes of chromatin engagement by distinct families of histone-binding effector domains. Recent work has also turned to how recently defined effector domains, including the YEATS domain, contribute to chromatin function and metabolic transcription
Sources: en.wikipedia.org
Traditional approaches in treating patients with DDD-resultant herniated discs oftentimes include discectomy—which, in essence, is a spine-related surgical procedure involving the removal of damaged intervertebral discs (either whole removal, or partially-based). The former of these two discectomy techniques involved in open discectomy is known as Subtotal Discectomy (SD; or, aggressive discectomy) and the latter, Limited Discectomy (LD; or, conservative discectomy). However, with either technique, the probability of post-operative reherniation exists and at a considerably high maximum of 21%, prompting patients to potentially undergo recurrent disk surgery. New treatments are emerging that are still in the beginning clinical trial phases. Glucosamine injections may offer pain relief for some without precluding the use of more aggressive treatment options. Adult stem cell or cell transplantation therapies for disc regeneration are in their infancy of development, but initial clinical trials have shown cell transplantation to be safe and initial observations suggest some beneficial effects for associated pain and disability. An optimal cell type, transplantation method, cell density, carrier, or patient indication remains to be determined. Investigation into mesenchymal stem cell therapy knife-less fusion of vertebrae in the United States began in 2006 and a DiscGenics nucleus pulposus progenitor cell transplantation clinical trial has started as of 2018 in the United States and Japan.
Goodpasture syndrome (GPS), also known as anti–glomerular basement membrane disease, is a rare autoimmune disease in which antibodies attack the basement membrane in lungs and kidneys, leading to bleeding from the lungs, glomerulonephritis, and kidney failure. It is thought to attack the alpha-3 subunit of type IV collagen, which has therefore been referred to as Goodpasture's antigen. Goodpasture syndrome may quickly result in permanent lung and kidney damage, often leading to death. It is treated with medications that suppress the immune system such as corticosteroids and cyclophosphamide, and with plasmapheresis, in which the antibodies are removed from the blood. Due to the GPS's rapid progression, the significant difficulty of treating the disease is identifying it early and making the appropriate response before severe damage occurs to the kidneys and or lungs. Consequently, the standard treatment plan of corticosteroids, cyclophosphamide, and plasmapheresis is vigorous and fast-acting, including high plasma volume exchange and an intensive dose of corticosteroid and cyclophosphamide based on the patient's body weight in kilograms. The disease was first described by an American pathologist Ernest Goodpasture of Vanderbilt University in 1919 and was later named in his honor.
=== Immune cells and inflammatory signaling === Macrophages present in the lesion environment differentiate into Multinucleated Giant Cells after prolonged activation. Secreted matrix metalloproteinases degrade collagen and fuel necrobiosis in response to immune activation. T cells, prominent in NL (Th-1 type cytokines) inhibit healing by the production of IFN-γ, suppressing M2 repair. These factors suggest a link to autoimmune conditions, as these factors explain a pro-inflammatory feedback loop.
An etorphine antidote Large Animal Revivon contains mainly diprenorphine for animals and a human-specific naloxone-based antidote, which should be prepared prior to the etorphine. A 5–15 mg dose is enough to immobilise an African elephant and a 2–4 mg dose is enough to immobilise a black rhinoceros.
The Zostavax vaccine (both single dose and two-dose regime) is likely effective at protecting people from herpes zoster disease for a duration of up to three years. The degree of longer term protection (beyond 4 years from the initial vaccination) is not clear. The need for re-vaccination after the first full vaccine schedule is complete remains to be confirmed. Zostavax was shown to reduce the incidence of shingles by 51% in a study of 38,000 adults aged 60 and older who received the vaccine. The vaccine also reduced by 67% the number of cases of postherpetic neuralgia (PHN) and reduced the severity and duration of pain and discomfort associated with shingles, by 61%. The FDA originally recommended it for individuals 60 years of age or older who are not severely allergic to any of its components and who meet the following requirements:
Sources: en.wikipedia.org
Dry lyophilized powder tolerates short ambient exposure during handling and shipping. Long-term room-temperature storage is not recommended because moisture uptake and slow degradation can occur over months. Storage at minus twenty degrees Celsius is the common practice for extended periods.
Typical entries list appearance, identity by mass spectrometry, purity by chromatography, water or moisture content, and residual counter-ion. Some certificates also report microbial limits and endotoxin for materials intended for laboratory use. The reported methods and acceptance ranges vary between suppliers.
The peptide is often supplied as an acetate or trifluoroacetate salt, and the counter-ion affects solubility, weight-per-mole calculations, and compatibility with cell assays. Trifluoroacetate can be undesirable in some biological experiments. Knowing the salt form is necessary for accurate concentration determination.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.